Your browser doesn't support javascript.
loading
Pediatric Precursor B-Cell Lymphoblastic Malignancies: From Extramedullary to Medullary Involvement.
Kroeze, Emma; Arias Padilla, Laura; Bakker, Max; Boer, Judith M; Hagleitner, Melanie M; Burkhardt, Birgit; Mori, Takeshi; Attarbaschi, Andishe; Verdú-Amorós, Jaime; Pillon, Marta; Anderzhanova, Liliya; Kabícková, Edita; Chiang, Alan K S; Kebudi, Rejin; Mellgren, Karin; Lazic, Jelena; Jazbec, Janez; Meijerink, Jules P P; Beishuizen, Auke; Loeffen, Jan L C.
Affiliation
  • Kroeze E; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
  • Arias Padilla L; NHL-BFM Study Center and Pediatric Hematology and Oncology, University Hospital Muenster, 48149 Muenster, Germany.
  • Bakker M; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
  • Boer JM; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
  • Hagleitner MM; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
  • Burkhardt B; NHL-BFM Study Center and Pediatric Hematology and Oncology, University Hospital Muenster, 48149 Muenster, Germany.
  • Mori T; Department of Hematology and Oncology, Hyogo Prefectural Kobe Children's Hospital, Kobe 650-0047, Japan.
  • Attarbaschi A; Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, 1090 Vienna, Austria.
  • Verdú-Amorós J; Pediatric Oncology Department, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain.
  • Pillon M; Clinic of Pediatric Hemato-Oncology, Department of Women's and Children's Health, University of Padova, 46010 Padova, Italy.
  • Anderzhanova L; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 117198 Moscow, Russia.
  • Kabícková E; Department of Pediatric Hematology and Oncology, Charles University, 2nd Medical School and University Hospital Motol, 150 06 Prague, Czech Republic.
  • Chiang AKS; Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.
  • Kebudi R; Division of Pediatric Hematology-Oncology, Istanbul University, Oncology Institute, 34452 Istanbul, Turkey.
  • Mellgren K; Department of Pediatric Oncology, Sahlgrenska University Hospital, University of Gothenburg, 413 45 Gothenburg, Sweden.
  • Lazic J; Department for Hematology and Oncology, University Children's Hospital, University of Belgrade, 11000 Belgrade, Serbia.
  • Jazbec J; Division of Pediatrics, Hematology and Oncology, University Medical Center Ljubljana, SI-1000 Ljubljana, Slovenia.
  • Meijerink JPP; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
  • Beishuizen A; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
  • Loeffen JLC; Erasmus Medical Center, Sophia Children's Hospital, 3015 CN Rotterdam, The Netherlands.
Cancers (Basel) ; 14(16)2022 Aug 12.
Article in En | MEDLINE | ID: mdl-36010889
ABSTRACT
B-cell lymphoblastic lymphoma (BCP-LBL) and B-cell acute lymphoblastic leukemia (BCP-ALL) are the malignant counterparts of immature B-cells. BCP-ALL is the most common hematological malignancy in childhood, while BCP-LBL accounts for only 1% of all hematological malignancies in children. Therefore, BCP-ALL has been well studied and treatment protocols have changed over the last decades, whereas treatment for BCP-LBL has stayed roughly the same. Clinical characteristics of 364 pediatric patients with precursor B-cell malignancies were studied, consisting of BCP-LBL (n = 210) and BCP-ALL (n = 154) patients. Our results indicate that based on the clinical presentation of disease, B-cell malignancies probably represent a spectrum ranging from complete isolated medullary disease to apparent complete extramedullary disease. Hepatosplenomegaly and peripheral blood involvement are the most important discriminators, as both seen in 80% and 95% of the BCP-ALL patients and in 2% of the BCP-LBL patients, respectively. In addition, we show that the overall survival rates in this cohort differ significantly between BCP-LBL and BCP-ALL patients aged 1−18 years (p = 0.0080), and that the outcome for infants (0−1 years) with BCP-LBL is significantly decreased compared to BCP-LBL patients of all other pediatric ages (p < 0.0001).
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Language: En Journal: Cancers (Basel) Year: 2022 Document type: Article Affiliation country: Países Bajos

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Language: En Journal: Cancers (Basel) Year: 2022 Document type: Article Affiliation country: Países Bajos